Kare Schultz Becomes Lundbeck’s CEO As New Launches Gather Pace
This article was originally published in The Pink Sheet Daily
One of the first priorities for Lundbeck’s new chief executive will be supporting new product launches worldwide to boost the Danish company’s geographic and product diversification.
You may also be interested in...
Candidates for the post in the Danish biotech are likely to have a commercial background, as Wiinberg-inspired strategy of geographic expansion and a growing a pipeline of CNS products continues to bear fruit.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.